Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2025)

Assembly Biosciences has reported Current Deferred Revenue over the past 9 years, most recently at $36.9 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $36.9 million for Q4 2025, down 1.91% from a year ago — trailing twelve months through Dec 2025 was $36.9 million (down 1.91% YoY), and the annual figure for FY2025 was $36.9 million, down 1.91%.
  • Current Deferred Revenue for Q4 2025 was $36.9 million at Assembly Biosciences, down from $42.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ASMB hit a ceiling of $86.3 million in Q4 2023 and a floor of $2.7 million in Q3 2021.
  • Median Current Deferred Revenue over the past 5 years was $35.0 million (2024), compared with a mean of $32.7 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 75.06% in 2021 and later soared 3057.48% in 2023.
  • Assembly Biosciences' Current Deferred Revenue stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then soared by 3057.48% to $86.3 million in 2023, then tumbled by 56.4% to $37.6 million in 2024, then fell by 1.91% to $36.9 million in 2025.
  • The last three reported values for Current Deferred Revenue were $36.9 million (Q4 2025), $42.4 million (Q3 2025), and $40.9 million (Q2 2025) per Business Quant data.